A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
Launched by GRÜNENTHAL GMBH · Jan 25, 2010
Trial Information
Current as of April 25, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symmetrical painful diabetic peripheral neuropathy
- Exclusion Criteria:
- • History of hypersensitivity, allergy or contraindication to opioids and acetaminophen
- • Confounding painful conditions
- • Significant vascular disease
- • History or risk of seizure
- • Chronic disease that might effect drug absorption, distribution, metabolism, or excretion
- • Female subjects who are being pregnant or breastfeeding
- • Evidence or history of alcohol, medication, or drug abuse
Trial Officials
Study Director
Study Director
Grünenthal GmbH
About Grünenthal Gmbh
Grünenthal GmbH is a global, research-based pharmaceutical company headquartered in Aachen, Germany, dedicated to the development of innovative therapies for pain management and related conditions. With a strong commitment to advancing science and improving patient outcomes, Grünenthal leverages its expertise in pharmacology and drug development to deliver effective and safe treatment options. The company actively engages in clinical trials to explore new therapeutic avenues, emphasizing patient-centric approaches and collaboration with healthcare professionals. Through its robust pipeline and dedication to quality, Grünenthal aims to address unmet medical needs and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Santa Ana, California, United States
Fairhope, Alabama, United States
Homewood, Alabama, United States
Tucson, Arizona, United States
Escondido, California, United States
Fullerton, California, United States
Long Beach, California, United States
Northridge, California, United States
Northridge, California, United States
Northridge, California, United States
San Francisco, California, United States
Santa Ana, California, United States
Santa Ana, California, United States
Santa Ana, California, United States
Vista, California, United States
Vista, California, United States
Waterbury, Connecticut, United States
Deerfield Beach, Florida, United States
Deerfield Beach, Florida, United States
Deerfield Beach, Florida, United States
Deerfield Beach, Florida, United States
Deerfield Beach, Florida, United States
Deerfield Beach, Florida, United States
Fort Myers, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Orlando, Florida, United States
Orlando, Florida, United States
Sarasota, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Leawood, Kansas, United States
Paducah, Kentucky, United States
Baltimore, Maryland, United States
East Bridgewater, Massachusetts, United States
Las Vegas, Nevada, United States
Princeton, New Jersey, United States
New York, New York, United States
Rochester, New York, United States
Asheville, North Carolina, United States
High Point, North Carolina, United States
Canton, Ohio, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Toledo, Ohio, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Austin, Texas, United States
Corpus Christi, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Provo, Utah, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
